Improved survival rates for veterans with de novo mHSPC – Prostate Cancer Foundation

Prostate Cancer Foundation shared a post on X:

“VA study shows improved survival rates for veterans with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Combination therapy is now used in 70% of cases.

Dr. Bruce Montgomery, Neeraj Agarwal and Martin Schoen discuss on Urotoday.”

Read further.

More posts featuring Prostate Cancer Foundation.

Blog Posts

Bruce Montgomery cancer Martin Schoen Metastatic Hormone-sensitive Prostate Cancer mHSPC Neeraj Agarwal OncoDaily Oncology UroToday